Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: The impact of KRAS mutations on VEGF-A production and tumour vascular network

Figure 5

GLUT-1 and Carbonic anhydrase IX immunostaining in KRAS ASP13 and CYS12 tumours. A) The percentage of GLUT-1 positive cells did not differ in CYS12 and ASP13. Intensity was higher in CYS12 tumors. B) The percentage of Carbonic anhydrase IX positive cells and the intensity of the immunostaining is higher in CYS12 tumors. C) Table depicts the percentage of Carbonic anhydrase positive cells. ASP13: 11.67 ± 3.07% vs CYS12: 48.57 ± 7.9%; P < 0.002).

Back to article page